Dr Reddys Laboratories Ltd Q1 FY27 Earnings Analysis

- Emerging Markets: Robust growth of 29% YoY in Q4FY26 and 23% in FY26; driven by new product launches and higher volumes, especially in Rest of World. - India: Double-digit growth of 20% YoY in Q4FY26 and 16% in FY26; supported by innovation franchise, new brands, price increases, and volume growth. - European Business: Decline of 3% YoY in Q4FY26 due to price erosion; acquisition-led growth of 37% YoY in FY26; expanded portfolio with 38 new products in FY26. - PSAI Business: Expected improvement with sequential growth; focus on global filings (48 in Q4, 128 in FY26). - Semaglutide: Anticipated to drive double-digit growth, with 12 million units targeted in FY27; oral formulation expected to grow in India and emerging markets. - Biosimilars: Expected break-even post Abatacept launch in FY28; new biosimilar launches planned to provide double-digit growth. - New Product Launches: 27 US product launches planned in FY27, expected to enhance growth. - Overall, company targets sustained double-digit growth across key markets and product lines.

- The company plans to maintain the base business EBITDA margin at around 20% without semaglutide, aiming to reach close to 25% including semaglutide depending on sales volume and pricing. - FY26 adjusted EBITDA margin was about 25%, consistent with aspirations, with continued cost optimization expected to support margin improvement. - Double-digit growth is expected in the US business ex-lenalidomide in FY27, mainly driven by biosimilars, consumer health, and certain 505(b)(2) products. - Growth in emerging markets and India is expected to continue, with new product launches and the upcoming oral semaglutide product contributing to healthy expansion. - Gross margins are targeted to remain above 50% considering product mix improvement, new product launches including semaglutide, and cost efficiency programs. - Adjusted EPS for FY26 was ₹51.42; future EPS growth is implied by expected margin expansion and revenue growth across key segments.

- The annual capital expenditure (capex) plan for the next year is around ₹2,000 crores. - Capex will be focused largely on biosimilars, certain product-specific investments, and general capex. - Future biologics products are expected primarily to come via partnerships, sharing R&D costs. - The company plans to qualify additional cartridge capacity (FTO11) potentially increasing capacity up to 40 million units by FY28, though current demand doesn't reflect the need yet. - Investments in CAR-T related programs have been discontinued, with impairments recognized. - Targeted ongoing investments will continue in branded franchises such as Nicotine Replacement Therapy (NRT) and branded generics. - R&D spends are expected to reduce due to completion of abatacept Phase III trials and AI-driven productivity improvements.

- There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript on Page 18 or surrounding pages. - The company reported a net cash surplus of ₹3,271 crores (US$349 million) as of March 31, 2026, indicating strong liquidity (Page 5). - Annual capex plans of around ₹2,000 crores for the next year were shared, funded through existing cash flows and cash reserves (Page 17). - No indication of raising fresh capital via debt or equity was discussed during the Q&A or management commentary. - The focus appears to be on operational cash flow generation and strategic investments without mentioning external fundraising.

The transcript provided on page 18 and surrounding pages does not explicitly mention current or expected order book or pending orders details. However, relevant inferred points include: - Semaglutide launches planned in multiple emerging markets with expectations of around 3-4 million pens sold per quarter, totaling close to 12 million units for FY27. - Ongoing filings and approvals in markets like Brazil, Canada, Turkey, and other emerging markets indicating active order potential. - Biosimilar launches like abatacept expected in calendar year 2027 (FY28), contributing to future order inflows. - Launch of 27 new generic products expected in the US in FY27, signaling a healthy order pipeline. - Partnerships in emerging markets for product distribution suggest order flow through B2B channels. No specific numeric order book or directly pending orders disclosed in the transcript.